Journal
CANCERS
Volume 12, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/cancers12113447
Keywords
liquid biopsy; ovarian cancer; metabolome; proteome; LC-MS/MS; FIA-MS/MS; biomarker; OMICS integrated analysis
Categories
Funding
- Bio and Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT) [NRF-2017M3A9B8069610, NRF-2017R1A2B2008505, NRF-2019M3A9B4030961, NRF-2019M3E5D3073106, NRF-2019M3E5D3073369]
Ask authors/readers for more resources
The 5-year survival rate in the early and late stages of ovarian cancer differs by 63%. In addition, a liquid biopsy is necessary because there are no symptoms in the early stage and tissue collection is difficult without using invasive methods. Therefore, there is a need for biomarkers to achieve this goal. In this study, we found blood-based metabolite or protein biomarker candidates for the diagnosis of ovarian cancer in the 20 clinical samples (10 ovarian cancer patients and 10 healthy control subjects). Plasma metabolites and proteins were measured and quantified using mass spectrometry in ovarian cancer patients and control groups. We identified the differential abundant biomolecules (34 metabolites and 197 proteins) and statistically integrated molecules of different dimensions to better understand ovarian cancer signal transduction and to identify novel biological mechanisms. In addition, the biomarker reliability was verified through comparison with existing research results. Integrated analysis of metabolome and proteome identified emerging properties difficult to grasp with the single omics approach, more reliably interpreted the cancer signaling pathway, and explored new drug targets. Especially, through this analysis, proteins (PPCS, PMP2, and TUBB) and metabolites (L-carnitine and PC-O (30:0)) related to the carnitine system involved in cancer plasticity were identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available